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MLL-AF4+ infant B cell acute lymphoblastic leukemia
is characterized by an early onset and dismal sur-
vival. It initiates before birth, and very little is known
about the early stages of the disease’s develop-
ment. Using a conditionalMll-AF4-expressingmouse
model in which fusion expression is targeted to the
earliest definitive hematopoietic cells generated in
the mouse embryo, we demonstrate that Mll-AF4 im-
parts enhanced B lymphoid potential and increases
repopulation and self-renewal capacity during a
putative pre-leukemic state. This occurs between
embryonic days 12 and 14 and manifests itself
most strongly in the lymphoid-primed multipotent
progenitor population, thus pointing to a window of
opportunity and a potential cell of origin. However,
this state alone is insufficient to generate disease,
with the mice succumbing to B cell lymphomas
only after a long latency. Future analysis of the mo-
lecular details of this pre-leukemic state will shed
light on additional events required for progression
to acute leukemia.
INTRODUCTION
While many pediatric leukemias have enjoyed significant ad-
vances in treatment in recent years that dramatically increase
long-term survival rates, infant leukemia associated with the
MLL-AF4 fusion continues to have a dismal prognosis. Among
infant leukemias, MLL-AF4 is the most frequent translocation
and results in an aggressive disease with a very early onset (<1
year of age), characterized by a pro-B acute lymphoblastic
leukemia (ALL) phenotype or, in some cases, biphenotypic leu-
kemia (Sanjuan-Pla et al., 2015). Studies on monozygotic twins
and the retrospective analysis of blood taken at birth have estab-
lished that MLL-AF4-associated leukemia has a prenatal origin
(Greaves, 2005). Furthermore, the observation that leukemic
cells carry no or infrequent additional mutations, together with
the early onset, rapid progression, and the fact that it can present
itself with ALL or a biphenotypic disease, has led to the sug-
gestion that the cell of origin is a developmentally restricted
embryonic/fetal progenitor that does not exist in the adult he-
matopoietic system (Andersson et al., 2015; Daser and Rabbitts,
2005). It is proposed that this cell has unique properties that
might include a more permissive chromatin state and a less
restricted differentiation potential, facilitating its transformation.
The in utero origin of MLL-AF4-associated infant leukemia
poses a major challenge to the study of this malignancy. For
this reason a faithful in vitro or animal model is required to allow
analysis of the early changes in the blood system that lead to leu-
kemia development. Such models are also a prerequisite for
elucidating the pathogenesis of the disease, as well as testing
treatments. A number of different models have been established,
which range from transduction of human embryonic stem cells
(ESCs) and cord blood cells to the generation of genetic mouse
lines, none of whichwas able to faithfully recapitulate the disease
in infant patients (Bueno et al., 2012; Bursen et al., 2010; Chen
et al., 2006; Krivtsov et al., 2008; Metzler et al., 2006; Montes
et al., 2011). The transduction of human ESCs and cord blood
cells with MLL-AF4 did not result in transformation; however, it
altered the differentiation path of ESCs, enhancing hemogenic
precursors, which were then skewed toward the endothelial
lineage (Bueno et al., 2012). By contrast, in cord blood cells,
MLL-AF4 caused a slight increase in engraftment potential,
myeloid CFU-C output, proliferation, and survival (Montes
et al., 2011). Interestingly, while transduction of mouse Lin-
Sca1+ cells with MLL-AF4 (albeit at very low transduction effi-
ciencies) had no effect, transduction with the reciprocal fusion
AF4-MLL produced pro-B ALL with a long latency (Bursen
et al., 2010).
To study disease development in vivo, a number of genetic
mouse models have been generated. A straight Mll-AF4 knockin
(Chen et al., 2006) and a conditional invertor line (Metzler et al.,
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2006), in which expression of Mll-AF4 was induced with
lymphoid-specific Cre recombinases, both produced more
mature B lymphomas with a very long latency. A conditional
knockin line, in which Mll-AF4 was induced by Mx1-Cre in adult
animals, developed both pre-B ALL and acute myeloid leukemia
(AML) with a shorter latency that was still around 150 days (Krivt-
sov et al., 2008). The reasons for the failure to recapitulate the
phenotype of the human disease are unknown; however, they
may include the following: (1) additional mutations and/or the
presence of both fusion products are required, or (2) the models
failed to target the right cell in the right cellular context.
As recent sequencing studies have revealed that MLL-AF4+
infant leukemias do not seem to require any additional mutations
apart from the initial translocation (Andersson et al., 2015; Bar-
dini et al., 2011), we decided to concentrate on the second pos-
sibility. We used the conditional invertor line (Metzler et al., 2006)
and targeted oncogene expression to the first definitive blood
cells. We then analyzed how this affected blood development
in the embryo and fetus, and we demonstrated that Mll-AF4
enhances lymphoid output and self-renewal in hematopoietic
stem cells (HSCs) and immature progenitors during a restricted
developmental window. The identification of this window of op-
portunity and a potential cell of origin now allows us to dissect
the molecular details of the initial changes produced by MLL-
AF4-induced transformation, which may highlight points of
therapeutic intervention.
RESULTS
Mll1 Is Widely Expressed in the Developing
Hematopoietic System
Since the expression of the Mll-AF4 fusion gene is controlled by
the regulatory elements of the endogenousmurineMll1 gene, we
analyzedMll1 expression in mouse embryonic and fetal hemato-
poietic tissues, as well as sorted cell populations, by qPCR to
narrow down the potential target cells for transformation. There
are four major hematopoietic sites during mammalian develop-
ment (reviewed in Medvinsky et al., 2011 andMirshekar-Syahkal
et al., 2014). The aorta-gonads-mesonephros (AGM) region is
the first location in which adult-repopulating HSCs are detected,
starting from embryonic day (E)10.5 (Medvinsky and Dzierzak,
1996; M!uller et al., 1994). Prior to HSC emergence, the yolk
sac provides a variety of primitive and definitive blood cells
and progenitors, which are essential for embryonic survival (re-
viewed in Frame et al., 2013). More recently, the placenta also
was described as being a rich source of hematopoietic stem
and progenitor cells (Alvarez-Silva et al., 2003; Gekas et al.,
2005; Ottersbach and Dzierzak, 2005), with a peak at E12. Cells
from all of those sites contribute to the colonization of the fetal
liver (FL), which, starting from E12, takes over as the main he-
matopoietic organ of the fetus.
Analysis of RNA extracted from whole tissues at stages that
cover their peaks of hematopoietic activity showed that Mll1 is
expressed in all of the tissues at all time points analyzed,
with the highest levels in the AGM and FL (Figure 1A). To look
more specifically at the expression ofMll1 in hematopoietic cells
(HCs), we sorted HSC-enriched populations (hematopoietic
stem and progenitor cell [HSPC], HSC/multipotent progenitor
[MPP], and ESLAM) and all the remaining HCs from these tis-
sues. In addition, we isolated a recently described progenitor
that has myeloid and lymphoid potential but lacks erythroid
and megakaryocyte capacity (Böiers et al., 2013). This im-
mune-restricted progenitor appears to be the embryonic coun-
terpart of the lymphoid-primed MPP (LMPP) identified by the
same group previously (Adolfsson et al., 2005), and it is a prime
candidate for the cell of origin for MLL-AF4+ infant leukemia due
to its dual lymphoid-myeloid potential (Malouf and Ottersbach,
2013). We found Mll1 expression in all of these cell types, sug-
gesting a widespread expression of Mll1 in the hematopoietic
system (Figure 1B).
To obtain a better picture of the spatial pattern ofMll1 expres-
sion, we also performed immunohistochemistry with an antibody
to Mll1 on embryo sections. Within the AGM, Mll1 was found in
circulating HCs in the aortic lumen (white arrowhead in Figures
1C, inset, and 1D), in sub-aortic mesenchymal cells (yellow
arrowhead in Figures 1C, inset, and 1D), in the mesonephric
duct (green arrowhead in Figure 1C), in cells of the sympathetic
nervous system (Figure 1C, inset), and in the tips of the urogenital
ridges (Figure 1C). Co-staining with antibodies to ckit and CD34
revealed that Mll1 also is found in cells of intra-aortic clusters,
which are believed to be sites of hematopoietic stem and pro-
genitor emergence (white arrows in Figures 1D and 1E). Cells
that were positive for all three markers also were found in the
E14 fetal liver (Figure 1F). There was widespread expression of
Mll1 in the placenta, with cells in and around the major vessel,
including the umbilical artery, also being stained (Figure 1G).
Mll-AF4 Expression Does Not Significantly Alter
Embryonic/Fetal Blood Composition
To study the effect of MLL-AF4 expression on embryonic and
fetal blood cells, we obtained the conditional Mll-AF4 invertor
mouse line (Metzler et al., 2006) and crossed it with the Vav-
Cre (Stadtfeld and Graf, 2005) or VE-Cadherin (VEC)-Cre line
(Chen et al., 2009) (Figure 2A). Vav-Cre targets all of the definitive
Figure 1. Mll1 Displays a Widespread Expression Pattern during Development
(A and B) The qPCR for Mll1 expression was performed on (A) whole tissues (n = 2–6) or (B) sorted HC populations (n = 1–5). HSPC, CD34+ ckit+; HC, CD45+
CD34!CD19!; HSC/MPP, Lin!B220!CD19! ckit+ CD45+ Sca1+ Flt3! IL7R!; LMPP, Lin!B220!CD19! ckit+ CD45+ Sca1+ Flt3+; ESLAM, EPCR+CD45+
CD150+ CD48!. Error bars indicate SEM.
(C–G) Immunohistochemistry was performed showingMll1 protein presence in the (C) E11 AGM (Mll1, red; CD34, green; DAPI, blue; inset, enlargement of boxed-
in area; green arrowhead, Mll1 expression in mesonephric ducts; white arrowhead, expression in circulating cells; yellow arrowhead, expression in sub-aortic
mesenchymal cells; DA, dorsal aorta; M, myotome; SNS, sympathetic nervous system; UGR, urogenital ridges; 320 objective); (D) E11 dorsal aorta (Mll1, red;
ckit, white; DAPI, blue; yellow arrowhead, Mll1 expression in the sub-aortic mesenchyme; white arrowhead, expression in circulating ckit+ cells; white arrow,
expression in ckit+ intra-aortic cluster cells; 3100 objective); (E) E11 dorsal aorta; Mll1, red; ckit, white; CD34, green; DAPI, blue; white arrow, expression in
ckit+CD34+ intra-aortic cluster cells; 3100 objective); (F) E14 FL (Mll1, red; ckit, white; CD34, green; DAPI, blue; white arrow, cell showing co-expression of all
three markers; 363 objective); and (G) E12 placenta (Mll1, red; CD34, green; DAPI, blue; UA, umbilical artery; 35 objective).
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Figure 2. Mll-AF4 Is Expressed following Recombination Mediated by Vav-Cre or VEC-Cre
(A) Schematic diagram shows fusion gene generation.
(B) Recombination efficiencies in E14 FL and adult blood. Standards and adult blood samples have the non-inverted band at the top and a Myo band for DNA
quantification at the bottom; E14 FL samples have the non-inverted band at the top and the inverted band at the bottom, which allows for direct quantification.
(legend continued on next page)
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HCs as early as E11, while VEC-Cre targets the precursors of
definitive HCs, the hemogenic endothelium (Chen et al., 2009).
While recombination efficiency in adult blood was equally high
with Vav-Cre and VEC-Cre (both reaching 100%), it was much
higher in total and CD45+ E14 FL cells following VEC-Cre-medi-
ated recombination compared with Vav-Cre-mediated recombi-
nation (Figure 2B). For this reason, we concentrated our analysis
predominantly on tissues derived from Mll-AF4 3 VEC-Cre
crosses.
We also checked for the expression of the fusion transcript in
CD45+ cells and were able to detect expression following VEC-
Cre induction as early as E11 in the AGM and at even higher
levels in the FL, while it was virtually non-detectable in those tis-
sues following Vav-Cre induction (Figures 2C and 2D). Transcript
levels increased in the E14 FL and remained markedly higher
with VEC-Cre as compared with Vav-Cre (Figures 2E and 2F).
In fact, Mll-AF4 expression in sorted cells from the E14 FL
following VEC-Cre recombination reached levels comparable
to the endogenous Mll1 gene from the remaining allele (Fig-
ure 2G). Specific progenitor populations in the bone marrow
(BM) of young mice also were analyzed, and they revealed
Mll-AF4 expression in HSC-enriched populations (HSC/MPP),
pre-pro-B and pro-B cells, the exact cell types implicated in
Mll-AF4+ leukemia (Figures 2H and 2I). The stromal microen-
vironment is increasingly recognized as a contributing factor
to the development of hematological malignancies (Krause
and Scadden, 2015). To determine whether VEC-Cre-induced
recombination leads to fusion gene expression in the microenvi-
ronment, defined BM stromal cell populations (Schepers et al.,
2013) were sorted and analyzed for Mll-AF4 transcript expres-
sion by qPCR. The highest expression was detected in endothe-
lial cells, with only low signals in mesenchymal stromal cells and
osteoblasts (Figure 2J).
To determine if Mll-AF4 expression altered blood production in
the embryo, specific hematopoietic populations were analyzed
by flow cytometry at different developmental time points. E11
AGM HSCs are enriched within the CD41intCD34+ckit+, while
E11 yolk sac (YS) HSCs are within the CD34+ckit+ population;
however, their percentages did not significantly differ between
the different genotypes (Figures S1A and S1B). As CD19 is virtu-
ally undetectable on the surface of E11 and E12 cells, we
restricted ourselves to B220 expression for the detection of
B cells, demonstrating that the percentage of B220+ cells was
unaltered in the AGM (Figure S1C). At E12, the FL begins to
take over as the most important hematopoietic organ in the
fetus. We therefore analyzed CD34+ckit+, B220+, and LMPP
numbers in E12 FL samples, and we also found these to be
unchanged (Figures S1D–S1F). Further enrichment for HSCs
can be achieved in the E14 FL with the EPCR+CD45+
CD150+CD48! (ESLAM) (Kent et al., 2009) phenotype. The per-
centages of these populations were again unaffected by the
presence of Mll-AF4 (Figure S1G), as were those of B cells and
LMPPs (Figures S1H and S1I).
Mll-AF4 Expression Is Associated with Modest Myeloid
Expansion
To assess the effect of Mll-AF4 expression on hematopoietic
progenitor function, dissociated FL cells from Mll-AF4 3 Vav-
Cre and Mll-AF4 3 VEC-Cre crosses were plated in methyl-
cellulose assays that promoted the growth of myeloid colonies.
Using E12 FL cells, a significant increase in total colony
numbers was noted upon Mll-AF4 expression (Figure 3A).
Furthermore, when the cells were collected from the plates
and analyzed for CD11b and Gr1 expression, an expansion of
CD11b+Gr1+ cells was demonstrated (Figure 3B). A similar
effect was observed with E14 FL cells, albeit slightly less
prominent (Figures 3C and 3D). To test the myeloid potential
of specific cell populations, HSCs/MPPs and LMPPs were
sorted from FL cells resulting from Mll-AF4 3 VEC-Cre crosses
and plated in methylcellulose. At both E12 and E14, a 2-fold in-
crease in total colonies was noted from HSCs/MPPs express-
ing Mll-AF4, while only colony-forming unit (CFU)-granulocyte,
monocyte (GM) output from LMPPs was significantly increased
(Figures 3E and 3F).
MLL fusions may confer properties of self-renewal on progen-
itor populations in vitro, whichwas tested through serial replating
in methylcellulose assays under myeloid conditions. E14 FL
HSCs/MPPs from the three controls failed to replate after the
third round, while Mll-AF4-expressing HSCs/MPPs were able
to give rise to colonies for another two rounds, at which point
the cells in the colonies had a CD45+ ckit+ CD11b! Gr1!
phenotype. After the fifth round they also exhausted, indicating
that full transformation had not been achieved (Figure 3G). We
also plated adult BM cells in myeloid colony-forming assays,
but we saw no difference in colony numbers between Mll-AF4-
expressing cells and Cre controls (Figure 3H); and, unlike FL
cells, Mll-AF4-expressing BM HSCs/MPPs did not replate after
the second round (Figure 3I).
(C and D)Mll-AF4 expression by qPCR in sorted CD45+ cells from E11 AGM and FL of indicated genotypes following (C) Vav-Cre recombination or (D) VEC-Cre
recombination. Numbers on x axis stand for individual embryos.
(E and F) Mll-AF4 expression by qPCR in CD45+ cells from E14 FL of indicated genotypes following (E) Vav-Cre recombination or (F) VEC-Cre recombination.
Numbers on x axis stand for individual embryos.
(G)Mll-AF4 andMll1 expression by qPCR in sorted E14 FL LMPP (Lin! B220!CD19! ckit+ CD45+ Sca1+ Flt3+) cells of indicated genotypes following VEC-Cre
recombination is shown.
(H)Mll-AF4 expression by qPCR in Lin!Sca1+ckit+ (LSK) cells sorted from adult BMof indicated genotypes following VEC-Cre recombination. Numbers on x axis
stand for individual mice.
(I) Mll-AF4 expression by qPCR in sorted BM populations of indicated genotypes following VEC-Cre recombination is shown (HSC/MPP, Lin! CD93+ CD24int
CD43+ B220! CD19! ckit+ IL7R!; pre-pro-B, Lin! CD93+ CD24+ CD43+ B220+ CD19! ckitint IL7Rint; and pro-B, Lin! CD93+ CD24+ CD43+ B220+ CD19+
ckit+ IL7R+).
(J) Endothelial cells (ECs, Lin! CD45! CD31+ Sca1+), mesenchymal stromal cells (MSCs; Lin! CD45! CD31! Sca1+ CD51+), and osteoblasts (OBs; Lin!
CD45! CD31! Sca1! CD51+) were sorted from Mll!AF4+ VEC!Cre+ adult BM and analyzed forMll-AF4 transcript expression by qPCR. Mll-AF4+ VEC-Cre+
E14 total FL cell cDNA was included as a positive control (n = 3). Error bars indicate SEM. See also Figure S1.
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Figure 3. Mll-AF4 Expression Leads to a Mild Myeloid Expansion
(A) Myeloid colony formation from E12 FL cells of the indicated genotypes is shown (n = 4–5).
(B) CD11b and Gr1 expression on cells isolated from E12 FL myeloid colony plates of the indicated genotypes is shown.
(C) Myeloid colony formation from E14 FL cells of the indicated genotypes is shown (n = 3–7).
(D) CD11b and Gr1 expression on cells isolated from E14 FL myeloid colony plates of the indicated genotypes is shown.
(legend continued on next page)
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Mll-AF4 Confers Enhanced Lymphoid Potential
MLL-AF4+ infant leukemia is predominantly associated with a
pro-B ALL phenotype. We therefore assessed the influence of
Mll-AF4 expression on B lymphoid potential in methylcellulose
assays. B lymphoid potential can be detected in the AGM as
early as E9.5 with a peak at E11 (Godin et al., 1999). When plated
directly in methylcellulose, AGM cells produced very few B cell
colonies; however, they were significantly enhanced when
Mll-AF4 was expressed (Figure 4A). Control E11 FL cells pro-
duced equally low numbers of lymphoid colonies, but this was
enhanced by >7-fold in the presence of Mll-AF4 (Figure 4B).
This obvious difference between control plates and Mll-AF4+
plates was very easily observable by eye (Figure 4C). In addition,
the colonies produced in the presence of Mll-AF4 tended to be
much larger (Figure 4D, bottom) than control colonies (Figure 4D,
top), indicating that Mll-AF4 not only increases the number of
progenitors but also enhances their proliferative capacity. The
cells collected from the Mll-AF4+ plates had a B220+CD19+
CD11b!Ter119! cell surface phenotype (Figure 4G).
The amplification of B lymphoid colonies was even more
significant at E12, reaching 7-fold and 8-fold following Vav-Cre
and VEC-Cre induction, respectively, with a significant differ-
ence between Vav-Cre and VEC-Cre (Figure 4E). To be able to
link this to a specific cell of origin, HSC/MPP and LMPP popula-
tions were isolated from E12 FL cells and plated in lymphoid as-
says. The results suggest that LMPPs are the major contributors
to the enhanced B lymphoid output, with a 25-fold increase upon
Mll-AF4 expression (Figure 4F). Similar effects were observed
with E14 total FL and sorted cell populations (Figures 4H and
4I). The fold differences between Cre controls and Mll-AF4-ex-
pressing cells were 4.5- and 7-fold for Vav-Cre and VEC-Cre,
respectively, with total E14 FL cells. We also collected the cells
from the colony plates and analyzed their surface phenotype.
This revealed that Mll-AF4 expression causes an accumulation
of cells with a pro-B cell phenotype (Figure 4J), representing
the stage at which differentiation is blocked in patients.
A significantly increasedB lymphoid output alsowas observed
from Mll-AF4-expressing BM cells, albeit on a smaller scale
(3-fold; Figure 4K), supporting the existence of a window of
opportunity at E12–14. This difference in enhanced B lymphoid
output between FL and BM cells is particularly striking when
sorted HSC/MPP and LMPP populations are compared
(compare Figures 4I and 4L). The main contributor to increased
B lymphoid colonies from BM cells is likely the common
lymphoid progenitor (CLP) population, but not more differenti-
ated cells (Figure 4M). FL cells showed limited replating potential
in lymphoid conditions (Figure 4N). Only Mll-AF4-expressing
cells were able to give rise to secondary colonies upon replating,
and these failed to produce colonies in a further round.
MLL is an H3K4 methyltransferase that interacts with its target
genes via its N terminus and carries the methyltransferase activ-
ity in its C terminus. As a result of leukemogenesis-associated
translocations, the C terminus of MLL is replaced with the C ter-
minus of a number of fusion partners that share the ability to
interact with the super-elongation complex (SEC) and lead
to aberrant expression of MLL target genes (reviewed in Krivtsov
and Armstrong, 2007 and Slany, 2009). Another hallmark of MLL
fusion oncogenes is their ability to recruit the H3K79 methyl-
transferase DOT1L toMLL target genes, which results in charac-
teristically high levels of H3K79 methylation in MLL-rearranged
leukemias and makes DOT1L an attractive therapeutic target
(Daigle et al., 2011; Krivtsov et al., 2008).
To test whether thesemechanisms underlie the hematopoietic
changes we observed in the fetus, a number of small molecule
inhibitors were employed. I-BET151 is a recently described in-
hibitor of the BET family of proteins that mediates the interaction
of SEC with chromatin (Dawson et al., 2011). The disruption of
this interaction with I-BET151 was shown to interfere with leuke-
mogenesis induced by MLL fusions. We therefore added this in-
hibitor to B lymphoid assays, which significantly reduced the
number of colonies produced by Mll-AF4-expressing FL cells
(Figure S2A). We next tested two different inhibitors of DOT1L,
SGC0946 and EPZ-5676 (Daigle et al., 2013; Yu et al., 2012),
and we observed that these also significantly inhibited the
growth of B lymphoid colonies from Mll-AF4+ FL cells (Fig-
ure S2A). None of the inhibitors displayed any effect on control
colony formation (Figure S2B), although B lymphoid colony for-
mation from control cells was low. We therefore repeated the
inhibitor experiments with adult BM cells from mice that do not
yet show any obvious signs of disease (Figures S2C and S2D).
The effects of all three inhibitors were still stronger on Mll-AF4-
expressing cells, although I-BET151 displayed some degree of
toxicity on normal cells. These results indicate that the activity
of the Mll-AF4 fusion, via aberrant SEC and DOT1L recruitment,
is responsible for the expansion of lymphoid progenitors in our
model.
Mll-AF4 Endows HSCs with Enhanced Repopulation and
Self-Renewal Potential
Many leukemia oncogenes can confer self-renewal ability. To
assess the effect of Mll-AF4 on embryonic HSCs, hematopoietic
tissues from different developmental time points were trans-
planted in a non-competitive setting. The first tissue in which
adult-repopulating HSCs are detectable is the AGM region,
with HSC numbers peaking at E11 (Kumaravelu et al., 2002;
Medvinsky and Dzierzak, 1996). Interestingly, Mll-AF4 appears
to have a negative impact on emerging HSCs, as the fewest
number of mice were repopulated with Mll-AF4+ AGM cells
(E) Myeloid colony formation from sorted E12 FL HSC/MPP (Lin!B220!CD19! ckit+ CD45+ Sca1+ Flt3! IL7R!; n = 2, VEC; n = 4, MA4xVEC) and LMPP (Lin!
B220! CD19! ckit+ CD45+ Sca1+ Flt3+) cells is shown (n = 3 for both genotypes).
(F) Myeloid colony formation from sorted E14 FL HSC/MPP (n = 5, VEC; n = 7, MA4xVEC) and LMPP cells is shown (n = 5, VEC; and n = 4, MA4xVEC).
(G) Replating potential of E14 FL HSC/MPP of indicated genotypes in myeloid conditions is shown (n = 3–5).
(H) Myeloid colony formation from total adult BM cells of indicated genotypes is shown (n = 1, WT; n = 3, VEC; n = 2, MA4; and n = 4, MA4xVEC).
(I) Replating potential of adult BM HSC/MPP of indicated genotypes in myeloid conditions is shown (n = 3, VEC; n = 1, MA4; and n = 2, MA4xVEC).
Statistical analysis was performed using a one-way ANOVA with Tukey’s multiple comparisons test (****p < 0.0001, ***p < 0.001, **p < 0.01, and *p < 0.05). Error
bars indicate SEM.
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with the lowest level of chimerism (Figure 5A). Before the estab-
lishment of the FL as the main hematopoietic site, the HSC pool
is expanded in the placenta (Gekas et al., 2005; Ottersbach and
Dzierzak, 2005). At E12, the peak of expansion, Mll-AF4 expres-
sion had a positive effect on placental HSCs, resulting in all mice
being repopulated and overall reconstitution levels being higher
(Figure 5B). The recipientmice also presentedwith a higher white
blood cell (WBC) count (Figure 5C). After E12, the FL becomes
the main hematopoietic organ (Gekas et al., 2005; Kumaravelu
et al., 2002). Mice transplanted with E12 FL cells expressing
Mll-AF4 showed the highest level of donor chimerism in the pe-
ripheral blood (>90%), while mice injected with cells carrying the
non-inverted allele had reduced donor contribution (Figure 5D).
The latter is most likely due to the haploinsufficiency of wild-
type (WT) Mll1 (Ernst et al., 2004), a trend that was also observed
with the E12 placenta. Interestingly, within the donor population,
myeloid contribution was increased while T cells were reduced
(Figure 5E).
To assess the impact on self-renewal, secondary transplanta-
tions were performed. When BM cells of primary recipients
of E12 FL cells were injected into secondary recipients, all
mice receiving Mll-AF4-expressing cells were repopulated as
compared with 50% of recipients of Cre-only cells (Figure 5F).
There was also a dramatic difference in donor chimerism, overall
suggesting that Mll-AF4 imparts enhanced self-renewal capac-
ity. Secondary recipients of Mll-AF4+ cells also had higher
WBC counts (Figure 5G).
Mice receiving E14 FL Mll-AF4+ cells again showed the high-
est level of reconstitution (around 70%) compared with Cre-only
and Mll-AF4 non-inverted cells, the latter of which were again
impaired in their repopulation ability (Figure 5H). Donor contribu-
tion to the T cell lineage was again significantly reduced, and
there was also a trend toward higher B andmyeloid cell contribu-
tion (Figure 5I). In secondary transplantations, all recipients of
E14 FLMll-AF4-expressing cells were repopulated as compared
with 36% of recipients of Cre-only cells, and there was again a
significant difference in donor chimerism (Figure 5J) and a trend
toward higher WBC counts (Figure 5K). Donor cells also pro-
duced more B220+CD19+ compared to Cre-only cells (data
not shown). Mll-AF4-expressing E12 placenta cells also per-
formed better in secondary transplants than control cells (Fig-
ure 5L), with a slight increase in WBCs (Figure 5M). Furthermore,
unlike Cre-only cells, which did not reconstitute at all, Mll-AF4-
expressing cells were able to fully reconstitute tertiary recipients,
producing consistently higher levels of chimerism (Figure 5N)
and higher WBC counts (Figure 5O).
Mll-AF4 Expression in Embryonic Cells Causes B Cell
Lymphoma with a Long Latency
To determine whether targeting of Mll-AF4 expression to early
hematopoietic progenitors results in the development of leuke-
mia comparable to the disease found in infant patients, offspring
from Mll-AF4 3 Vav-Cre and Mll-AF4 3 VEC-Cre crosses were
monitored for disease development. Mice from these crosses
were born at normal Mendelian ratios and had no obvious
phenotype apart from a trend toward a lower body weight
(data not shown). All of the mice that expressed the fusion
gene died significantly earlier than their control littermates, how-
ever, only after a long latency (Figure 6A). The median survival
was 437 days for Mll-AF4+ VEC-Cre+ mice and 556 days for
Mll-AF4+ Vav-Cre+ mice, which is similar to what had been
observed previously when Mll-AF4 expression was targeted to
the lymphoid lineage (Metzler et al., 2006). Mll-AF4+ VEC-Cre+
mice seem to die slightly earlier than Mll-AF4+ Vav-Cre+ mice;
however, the difference was not significant.
The majority of the mice (74%) presented with B cell lym-
phomas, with three mice showing a T cell disease and three a
lymphoproliferative disease (Table 1). Almost all of the mice dis-
played pronounced splenomegaly and liver infiltration, and the
majority also developed mesenteric tumors (Table 1; Figures
6B–6D). A number of the mice also presented with mediastinal
tumors and kidney infiltration, but the BM and peripheral blood
were only rarely affected (Table 1). This disease phenotype
was similar to that observed in other MLL-AF4 mouse models
Figure 4. Mll-AF4 Expression Leads to Increased B Lymphoid Output
(A) B lymphoid colony formation from E11 AGM cells of the indicated genotypes is shown (n = 1, WT; n = 4, VEC; n = 3, MA4; and n = 4, MA4xVEC).
(B) B lymphoid colony formation from E11 FL cells of the indicated genotypes is shown (n = 1, WT; n = 2, VEC; n = 1, MA4; and n = 4, MA4xVEC).
(C) B lymphoid colony assay plates are shown.
(D) Representative examples show the type of B lymphoid colonies found on control plates (top) and plates that contain Mll-AF4-expressing cells (bottom), at the
same magnification (34).
(E) B lymphoid colony formation from E12 FL cells of the indicated genotypes is shown (n = 5).
(F) B lymphoid colony formation from sorted E12 FL HSC/MPP (Lin! B220! CD19! ckit+ CD45+ Sca1+ Flt3! IL7R!) and LMPP (Lin! B220! CD19! ckit+
CD45+ Sca1+ Flt3+) cells is shown (n = 3–4).
(G) Cell surface phenotype of cells collected from colonies is shown.
(H) B lymphoid colony formation from E14 FL cells of the indicated genotypes is shown (n = 3–8).
(I) B lymphoid colony formation from sorted E14 FL HSC/MPP (n = 2, VEC; and n = 4, MA4xVEC) and LMPP cells (n = 5, VEC; and n = 5, MA4xVEC) is shown.
(J) Percentage of cells with a ckit+ or pro-B phenotype collected from B lymphoid plates that had been seeded with sorted (HSC/MPP or LMPP) E14 FL cells of
indicated phenotypes is shown.
(K) B lymphoid colony formation from BM cells of the indicated genotypes (n = 1, WT; n = 3, VEC; n = 2, MA4; and n = 4, MA4xVEC) is shown.
(L) B lymphoid colony formation from sorted adult BM HSC/MPP (Lin! B220! CD19! ckit+ CD45+ Sca1+ Flt3! IL7R!) and LMPP (Lin! B220! CD19! ckit+
CD45+ Sca1+ Flt3+) cells (n = 3, VEC; and n = 2, MA4xVEC) is shown.
(M) B lymphoid colony formation from sorted adult BM CLP (Lin! CD93+ CD24int CD43+ B220! CD19! ckit+ IL7R+) and pro-B (Lin! CD93+ CD24+ CD43+
B220+ CD19+ ckit+ IL7R+) cells (n = 2, VEC; and n = 1, MA4xVEC) is shown.
(N) Replating potential of E14 FL HSC/MPP and LMPP of indicated genotypes in lymphoid conditions. Results are shown after one round of replating (n = 2).
Statistical analysis was performed using a one-way ANOVA with Tukey’s multiple comparisons test (****p < 0.0001, ***p < 0.001, **p < 0.01, and *p < 0.05). Error
bars indicate SEM. See also Figure S2.
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Figure 5. Mll-AF4-Expressing HSCs Have Higher Repopulation and Self-Renewal Activity
(A and B) Average donor contribution to the peripheral blood of all recipients of (A) E11 AGM cells (recipients n = 5, VEC; n = 2, MA4; n = 7, MA4xVEC) or (B) E12
placenta cells (recipients n = 6, VEC; n = 5,MA4; and n = 6,MA4xVEC) with the indicated genotypes. Percentages ofmice positive for repopulation are stated next
to the genotypes.
(C) White blood cell counts of mice reconstituted with E12 placenta cells at 16 weeks are shown.
(legend continued on next page)
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(Chen et al., 2006; Metzler et al., 2006; Tamai et al., 2011). We
analyzed some mice at a much earlier time point when they
were still asymptomatic, and we observed initial signs of the dis-
ease, i.e., splenomegaly and liver infiltration; however, disease
progression seems to be slow enough for these mice to survive
for a considerable time longer.
To ascertain if the primary disease is transplantable, we disso-
ciated the enlarged spleen of a diseased mouse (Figure 6D),
which usually contained a strong B cell and T cell component
(Figure 6E), and we injected the cells into secondary recipients.
Tumors did indeed develop in secondary recipients (Figure 6F),
which again had pronounced B and T cell components (Fig-
ure 6G). Interestingly, donor cells contributed both to the
B and T cell pools in the tumor (Figure 6H), while the recipient
almost exclusively contributed to the T cell component (Fig-
ure 6I). These likely represent infiltrating reactive T cells that
also have been observed by others (Metzler et al., 2006). Overall,
98% of the B cells were donor derived while 64% of the T cells
came from the donor and 36% from the recipient (Figure 6J).
Some of themice that had been transplanted with Mll-AF4-ex-
pressing fetal tissue to assess HSC function (Figure 5) also suc-
cumbed to hematological malignancies with a shorter latency
than non-transplanted mice (Table S1). They all showed spleno-
megaly to some degree as well as myeloid expansion. Involve-
ment of the liver and mesenteric and mediastinal tumors also
were observed in some cases. The strongest effect was again
observed in recipients of E12 FL, with the highest number of
sick mice and the strongest disease phenotype. One of the sec-
ondary recipients also developed the disease and with a slightly
shorter latency than the primary recipients.
DISCUSSION
In this study, we targeted the expression of Mll-AF4 to the first
definitive HCs that emerge during embryogenesis as well as their
precursors, the hemogenic endothelium, and we studied how
this affected hematopoietic development. Phenotypically, blood
development seemed largely unaffected with no major changes
to the percentages of HSPCs andmature blood cell types. This is
in contrast to the hematopoietic impairment that was observed
following virally driven expression of MLL-AF4 in hemogenic
precursors derived from ESCs (Bueno et al., 2012). However,
functional assays revealed that the expression of Mll-AF4 im-
parted greatly enhanced B lymphoid potential on HSCs/MPPs
and LMPPs at a time point during development when there is
hardly any B lymphoid output from WT cells in the absence of
stromal support (i.e., in methylcellulose assays). Considering
that the disease in infants manifests itself as pro B-ALL in the
majority of cases, this is highly significant and concurs with our
observation of an expansion of cells with a pro-B phenotype.
Althoughmyelopoiesis was only mildly affected, the self-renewal
of HSCs was greatly increased, again in keeping with the known
role of MLL-fusion proteins in malignant self-renewal.
Our results also provide evidence for the existence of the pre-
viously suggested developmental window of opportunity for this
disease to arise, as the strongest effect was observed with E12–
E14 tissues, mainly the FL. Enhancement of myelopoiesis and
repopulation activity was strongest in E12 fetal tissues, while
the increase in B lymphoid potential was most pronounced at
E14. Most importantly, the expansion of the pro-B cell stage
was not observed in adult Mll-AF4-expressing BM cells under
lymphoid-plating conditions. Furthermore, the majority of trans-
planted mice that succumbed to hematological disease had
been injected with E12 FL cells within this window. This observa-
tion was not due to these mice having higher repopulation levels,
since an increase in the injected dose of E14 FL cells by more
than 100-fold did not result in more mice getting sick and did
not accelerate the disease (data not shown). Our data also point
to the LMPP as a potential cell of origin, as it consistently gave
the highest response to Mll-AF4 expression in lymphoid assays
and in the expansion of pro-B cells, although such an effect,
albeit on a smaller scale, was already visible in the HSC/MPP
population.
The changes we observed—enhanced B lymphoid potential,
expansion of pro-B cells, and increased self-renewal—may be
reasonably described as the pre-leukemic state for this disease.
Having been able to capture this state, which is inaccessible in
human patients, now allows us to study in more detail the early
molecular changes induced by the expression of the fusion
gene. It also might provide some indication as to what is missing
(D) Donor contribution to the peripheral blood of recipients of E12 FL cells with the indicated genotypes (recipients n = 5, VEC; n = 7, MA4; and n = 7, MA4xVEC).
Percentages of mice positive for repopulation are stated next to the genotypes.
(E) Contribution to individual lineages at 16 weeks is shown.
(F) Donor contribution to the peripheral blood of secondary recipients of E12 FL cells at 16 weeks (recipients n = 6, VEC; and n = 6, MA4xVEC). Dots represent
individual mice and the total percentage of repopulated mice is given underneath.
(G) White blood cell counts of secondary recipients of E12 FL cells are shown.
(H) Donor contribution to the peripheral blood of recipients of E14 FL cells with the indicated genotypes (recipients n = 11, VEC; n = 5,MA4; and n = 14,MA4xVEC).
Percentages of mice positive for repopulation are stated next to the genotypes.
(I) Contribution to individual lineages at 16 weeks is shown.
(J) Donor contribution to the peripheral blood of secondary recipients of E14 FL cells at 16 weeks (recipients n = 11, VEC; and n = 10, MA4xVEC). Dots represent
individual mice and the total percentage of repopulated mice is given underneath.
(K) White blood cell counts of secondary recipients of E14 FL cells are shown.
(L) Donor contribution to the peripheral blood of secondary recipients of E12 placenta cells at 16 weeks (recipients n = 7, VEC; and n = 7, MA4xVEC). Dots
represent individual mice and the total percentage of repopulated mice is given underneath.
(M) White blood cell counts of secondary recipients of E12 placenta cells are shown.
(N) Donor contribution to the peripheral blood of tertiary recipients of E12 placenta cells at 16 weeks (recipients n = 4, VEC; and n = 4, MA4xVEC). Dots represent
individual mice and the total percentage of repopulated mice is given underneath.
(O) White blood cell counts of tertiary recipients of E12 placenta cells are shown.
Statistical analysis was performed using a Mann-Whitney test (****p < 0.0001, ***p < 0.001, **p < 0.01, and *p < 0.05). Error bars indicate SEM. See also Table S1.
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in our model that would convert this pre-leukemic state during
that window of opportunity into a short-latency, acute leukemia
akin to the disease found in infant patients. The late-onset
B lymphomas that result from our experimental approach
are similar to the models generated by others (Chen et al.,
2006; Metzler et al., 2006; Tamai et al., 2011), and they sug-
gest that we are still missing a key component(s) that drives
leukemogenesis.
Figure 6. Mll-AF4 Expression Causes B Lymphomas
(A) Kaplan-Meier survival plot. The control curve includes the pooled data from littermates with a WT, VEC-Cre only, Vav-Cre only, and Mll-AF4+Cre-genotypes
(***p < 0.001).
(B) Diseased mouse with a mesenteric tumor (black arrow) and an enlarged spleen (red arrow) is shown.
(C) H&E-stained section of a diseased liver shows malignant cell infiltration (arrow).
(D) Example shows splenomegaly with the enlarged spleen of an Mll-AF4-expressing mouse on the right and a control spleen on the left.
(E) Diseased spleens contain strong B and T cell components.
(F) Secondary mesenteric (black arrow) and bowl (red arrow) tumors following injection of diseased spleen cells into secondary recipients are shown.
(G–I) B and T cell components in the (G) mesenteric tumor, broken down into (H) donor and (I) recipient, are shown.
(J) Percentages of tumor cell populations that are derived from donor and recipient are shown.
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Several suggestions as to the identity of this factor have been
made and include failure to target the correct cell of origin. By us-
ing VEC-Cre to drive Mll-AF4 expression, all of the probable
target cells for the initial transformation should have been
covered. It has been shown that VEC-Cre labels endothelial cells
and circulating blood cells within the yolk sac as early as E8.5
and in the dorsal aorta by E9.5 (Alva et al., 2006; Chen et al.,
2009). The two major definitive progenitors that are present after
E8.5, the LMPP and the erythroid-myeloid progenitor (EMP), also
have been suggested to have a VE-Cadherin+ hemogenic endo-
thelial origin (Böiers et al., 2013; Frame et al., 2013; McGrath
et al., 2015). B-1 B cells predominate during fetal development,
and there is evidence that they can initiate B-ALL (Montecino-
Rodriguez et al., 2014). By crossing VEC-Cre with a ROSA26-
red fluorescent protein (RFP) line and analyzing RFP expression
in E14 FL B-1 B cells, we found more than 50% of B-1 B cells to
be labeled by VEC-Cre (data not shown). Taken together, these
data suggest that our approach targeted all the relevant
definitive hematopoietic populations. We also initiated Mll-AF4
expression in the germline by crossing the Mll-AF4 mouse line
with a Stella-Cre line, but we failed to retrieve any live Mll-AF4-
expressing embryos from as early as E8.5 (data not shown). Em-
bryonic lethality following germline expression of Mll-AF4 in this
conditional mouse line had been demonstrated previously (Met-
zler et al., 2006).
Other possible explanations for the lack of a patient-like
phenotype in the mouse models include the requirement of a
second hit; however, recent sequencing data argue against
this, and even KRAS mutations, which are occasionally present,
seem to impact on the timing of disease onset and the migration
of MLL-AF4-transduced cells, but they are not required for dis-
ease initiation (Andersson et al., 2015; Bardini et al., 2011; Prieto
et al., 2016; Tamai et al., 2011). Another explanation may be that
there are fundamental differences between mouse and human
hematopoietic development that prevent progression to B-ALL
in the murine context. To address this, we plan to analyze the
impact of MLL-AF4 expression in human FL cells in the future.
There is good evidence to suggest that the reciprocal fusion
gene, AF4-MLL, which is expressed in 50%–80% of patients,
plays an integral part in the development of the disease (Bursen
et al., 2010; Wilkinson et al., 2013). We tried to co-express AF4-
MLL in Mll-AF4-expressing cells by viral transduction; however,
due to the very large size of the AF4-MLL construct, transduction
efficiencies were extremely low and precluded any further ana-
lyses (data not shown). Answering this question may have to
await the generation of a true translocator mouse model of the
disease.
Finally, it has been reported that BM stromal cells from
MLL-AF4+ infant patients express the fusion gene, suggesting
a stromal involvement, and that a common progenitor for the
Table 1. Summary of Disease Phenotypes in Mll-AF4-Expressing Mice
Mouse ID Splenomegaly Mesenteric Disease Mediastinal Disease BM Peripheral Blood Liver Disease
Mll-AF4 3 Vav-Cre (Median Survival 556 Days)
3809 O – O O – O T cell lymphoma
4468 O O – – – O B cell lymphoma
4475 O – – – – O B cell lymphoma
4649 O O – – – O B cell lymphoma
4650 O O – – – O B cell lymphoma
5244 O O – – – – B cell lymphoma
5250 O – – – – O B cell lymphoma
5909 O – – – – O B cell lymphoma
5911 O O – O O O T cell lymphoma
Mll-AF4 3 VEC-Cre (Median Survival 437 Days)
6357 O – – – – O lymphoproliferative disorder
6703 O O – – – O lymphoproliferative disorder
6705 O O – – – O B cell lymphoma
6707 O O – – – O B cell lymphomaa
6709 O O – – – O B cell lymphoma
6713 O – – – O O lymphoproliferative disorder
6809 O O – – – O B cell lymphoma
6810 O O – – – O B cell lymphoma
7060 O O – – – O B cell lymphoma
7063 O O O – – O B cell lymphoma
7737 O O O – – O T cell lymphoma
7739 O O O – – O B cell lymphoma
8945 O O – – – – B cell lymphoma
0062 O – – – – O B cell lymphoma
aTransplanted.
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hematopoietic andmesenchymal lineagewas the initial target for
the translocation (Menendez et al., 2009). We detected low-
fusion-transcript expression in BM stromal cells following VEC-
Cre-mediated induction. Whether these are the same relevant
stromal cell types as in the patients is still unclear. We have ex-
pressed MLL-AF4 in stromal cell lines, but we found no signifi-
cant impact on their hematopoietic supportive activity (data
not shown). Culture homeostasis of patient-derived mesen-
chymal stromal cells also was shown to be normal (Menendez
et al., 2009); thus, the role of the microenvironment in MLL-
AF4+ infant leukemia requires further investigation. To test this
in an in vivo model would require the identification of a common
hematopoietic-mesenchymal progenitor and a way of geneti-
cally targeting it, an approach we will attempt to take in the
future.
In summary, our data demonstrate functional changes in he-
matopoietic development induced by the Mll-AF4 fusion in the
embryo, and they provide a description of a pre-leukemic state.
Further molecular dissection of this state may point to hurdles
that have to be overcome to achieve progression to pro-B




Heterozygous Mll-AF4loxP knockin (Metzler et al., 2006), heterozygous VEC-
Cre transgenic (Chen et al., 2009), and heterozygous Vav-Cre transgenic
(Stadtfeld and Graf, 2005) mice were crossed to produce embryos and adult
mice of the desired genotypes. For embryo generation, the morning of plug
detection was considered day 0. All animals were housed according to institu-
tional guidelines and experimental procedures had UK Home Office approval.
Single-Cell Preparations
Tissues were dissected from embryos (only the region around the chorionic
plate of the placenta was used) and dissociated by collagenase treatment
(Alfa Aesar; 0.125% in PBS; for AGM, yolk sac, and placenta) or by drawing
through a needle attached to a syringe (FL). Adult BMwas collected by flushing
the femur and tibia, and spleen and liver were mechanically dissociated on top
of a filter. Red blood cell lysis (Pharm LyseTM Buffer, Becton Dickinson [BD])
was performed on E14 FL cells, BM, spleen, liver, and peripheral blood. For
BM stroma collection, bones were crushed and treated with collagenase.
Flow Cytometry and Cell Sorting
The following antibodies were used to analyze cell populations from tissues or
colonies using combinations indicated in the text and/or the figure legends:
CD3e-APC (BD I45-2C11), Ter119-APC (eBioscience TER119), F4/80-APC
(BioLegend BM8), Nk1.1-APC (BD PK136), Gr1-APC (BD RB6-8C5), IL7R-
PE (eBioscience A7T34), Sca1-PB (BioLegend E13-161.7), ckit-APCeF780
(eBioscience 2B8), CD45-AF700 or CD45-FITC (eBioscience 30-F11), Flt3-
biotin (eBioscience A2F10), B220-PECy7 (BioLegend RA3-6B2), CD19-
PECy7 (BioLegend 1D2) and Qdot655 (Life Technologies), CD24-BV421
(BioLegend M1/69), B220-AF700 (eBioscience RA3-6B2), AA4.1-PECy7
(BioLegend AA4.1), CD19-BV605 (BioLegend 6D5), CD43-FITC (BioLegend
1B11), CD48-APC (eBioscience HM48-1), EPCR-PE (eBioscience 1560),
B220-FITC (eBioscience HIS24), CD41-PE (eBioscience MWReg30), CD11b-
APC (eBioscience M1/70), Gr1-PE (eBioscience RB6-8C5), CD19-eFluor450
(eBioscience 1D3), CD34-FITC (eBioscience RAM34), CD150-eFluor450
(eBioscience mShad150), CD31-PECy7 (BioLegend 390), and CD51-PE
(BioLegend RMV-7). Biotin antibodies were conjugated to Qdot655 streptavi-
din conjugate (Thermo Fisher Scientific). The lineage cocktail (Lin-) consisted
of antibodies against CD3e, Nk1.1, Gr1, Ter119, and F4/80. Dead cells were
excluded using SYTOX Dead Cell Stains (Life Technologies) or 7AAD (Invitro-
gen). Flow cytometry was performed on a CyAn ADP analyzer (Beckman
Coulter) or an LSR Fortessa (BD), and data were analyzed using FlowJo
software (Tree Star). Cells were sorted using a high-speed Influx or ARIA cell
sorter (BD).
Colony-Forming Assays
For myeloid assays, cells were plated in M3434 Methocult (STEMCELL Tech-
nologies) in triplicate at different concentrations, and colonieswere scored and
counted after 7 days. For lymphoid assays, cells were plated in M3630 Metho-
cult (STEMCELL Technologies) supplemented with 20 ng/ml stem cell factor
(SCF) and 20 ng/ml Flt3 (PeproTech) in triplicate at different concentrations,
and colonies were counted after 14 days. Where stated, DOT1L inhibitors
EPZ-5676 and SGC0946 (both Cambridge Bioscience) and BET protein inhib-
itor I-BET151 (Sigma) were added to the lymphoid methylcellulose medium at
the indicated concentrations.
Repopulation Assays
Cell preparations were injected intravenously into irradiated (9.5 Gy) recipients
that differed in their CD45 isoform expression. For the primary transplants, E11
AGM, E12 Plac, E12 FL, and E14 FL were injected at 1, 0.5, 0.5, and 0.004 em-
bryo equivalent per recipient, respectively, together with 100,000 total BM
helper cells. For the secondary and tertiary transplants, between two and
three million total BM cells (without helper cells) were injected, which were
normalized according to the level of donor chimerism. At the indicated time
points, donor contribution to the peripheral bloodwas analyzed by flow cytom-
etry using CD45.1-PE (eBioscience A20), CD45.2-FITC (eBioscience 104),
CD11b-eFluor450 (eBioscience M1/70), Gr1-AF700 (BioLegend RB6-8C5),
CD19-BV605 (BioLegend 1D2), B220-PECy7 (eBioscience RA3-6B2), CD3-
APC (BioLegend I45-2C11), and ckit-APCeFluor780 (eBioscience 2B8). Mice
were considered positive for repopulation if the donor contribution to the total
peripheral blood was >5%. Peripheral blood counts were performed on an
ABC blood counter (Woodley).
Immunohistochemistry and Histology
Cryosections were prepared from paraformaldehyde-fixed embryos and
stained with anti-Mll1 (Novus Biologicals and Bethyl Laboratories), anti-
CD34-FITC (eBioscience), anti-ckit (R&D Systems), followed by secondary an-
tibodies anti-rabbit AlexaFluor555, anti-goat-AlexaFluor555, and anti-rabbit
AlexaFluor647 (Abcam). Sections were mounted with DAPI-containing Vecta-
shield mounting medium (Vector Laboratories), images were obtained on an
AxioImager Z2 (Zeiss) fitted with a Hammamatsu Flash 4 V2 camera at room
temperature, and images were analyzed with the Zen Blue 2012 software.
Tissues from diseased mice were fixed in formalin and embedded in wax.
Sections were prepared and stained with H&E, dehydrated, and mounted in
DePeX-mounting medium (Fisher Scientific).
Gene Expression Analysis
RNA extraction from total embryonic tissue or sorted cells was achieved with
the QIAGENmiRNeasy mini or micro kit. Reverse transcription was carried out
with the iScript cDNA Synthesis Kit (Bio-Rad), and cDNA was quantified using
Power SYBR according to the manufacturer’s instructions. Primers used were
the following: MLL-F, 50-CACGGACTCCTAGAGCGAAC-30; MLL-R, 50-TTCTG
TGTTGCCTGGACCTC-30; Mll-AF4-F, 50-AGTGGGCATGTAGAGGGATC-30;
Mll-AF4-R, 50-ATGGCTCAGCTGTACTAGGC-30; b-actin-F, 50-TCCTGTCCT
CACTGTCCA-30; and b-actin-R, 50-GTCCGCCTAGAAGCACTTGC-30. The
qPCR reactions were run on an ABI7900HT.
Genotyping and Inversion Efficiencies
To determine the inversion efficiency, a three-way PCR was carried out
in which the two forward primers, one for the non-inverted version of
the construct (Mll-NonI) and one for the inverted construct (AIR), shared a
common reverse primer (Mll-In10). The sequences are as follows: Mll-NonI,
50-TCGCCTTCTTGACGAGTTCT-30; AIR, 50-CAAGGTTTCTAGCACTTACGAA
TTAATATGC-30; and Mll-In10, 50-ATGATGCCACTGTGCTGTGT-30. These
primers also were used for genotyping, together with primers for the detection
of Cre recombinase (CreF, 50-CTGACTGACGGTGGGAGAAT-30 and CreR,
50-CTTGCATGATCTCCGGTATT-30). In some cases, where PCR reactions
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only detected the non-inverted allele, primers were included for theMyogenin
gene (Myo1, 50-TTACGTCCATCGTGGACAGC-30 andMyo2, 50-TGGGCTGGG
TGTTAGTCTTA-30). PCR reactions were run on a Peltier Thermal Cycler.
Statistical Analysis
Graphs and statistical analysis were done using GraphPad Prism 6. Error bars
denote SEM and are included where at least three biological replicates were
obtained with three technical replicates each. The p values less than 0.05
were considered significant and were obtained using the non-parametric
Mann-Whitney test, the non-parametric Kruskal-Wallis test with Dunn’s multi-
ple comparisons, or a one-way ANOVA with Tukey’s multiple comparisons
test, as indicated in the figure legends. Survival rates were determined with
Kaplan-Meier survival plots. Where statistical significance was reached, this
is indicated by asterisks.
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Gekas, C., Dieterlen-Lièvre, F., Orkin, S.H., and Mikkola, H.K. (2005). The
placenta is a niche for hematopoietic stem cells. Dev. Cell 8, 365–375.
Godin, I., Garcia-Porrero, J.A., Dieterlen-Lièvre, F., and Cumano, A. (1999).
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Supplemental Figures: 
Figure S1: Mll-AF4 does not cause major changes to embryonic hematopoiesis. Related to Figure 2. 
The proportion of distinct hematopoietic cell populations was determined in embryonic tissues of indicated 
genotypes by flow cytometry. (A) HSPCs in the E11 YS, n=3-10; (B) HSPCs, n=3-6, and (C) B cells in the E11 
AGM, n=3-4; (D) HSPCs, n=3-10; (E) B cells, n=3-10 and (F) LMPPs (Lin- B220- CD19- ckit+ CD45+ Sca1+ 
Flt3+) in the E12 FL, n=2-7; (G) ESLAM (EPCR+ CD45+ CD150+ CD48-), n=5-8; (H) B cells, n=3-9, and (I) 
LMPPs in the E14 FL, n=3-7. Error bars = SEM. Statistical analysis was performed using the non-parametric 
Kruskal-Wallis test with Dunn’s multiple comparisons, but no significant differences were found. 
 
  
Figure S2: Mll-AF4 recruits SEC and DOT1L. Related to Figure 4. 
Effect of inhibitors of BET proteins (IBET) and DOT1L (SGC, EPZ) at indicated concentrations (PM) on B 
lymphoid colony formation from (A) E14 FL Mll-AF4-expressing cells, n=3-4; (B) E14 FL Cre-only control 
cells, n=2;  (C) adult BM (~1 year old, pre-morbid) Mll-AF4-expressing cells, n=2; (D) adult BM (~1 year old, 
pre-morbid) Cre-only control cells, n=2. Error bars = SEM. Statistical analysis was performed using a 
parametric one-way ANOVA with Tukey’s multiple comparisons test. **** p<0.0001, *** p<0.001, ** p<0.01. 
  
Supplemental Table S1: Disease development in transplant recipients. Related to Figure 5. 













E12 Plac 1/6 186 0 no donor cells 
expansion of recipient T 
cells  
0/6   




reduced B cells 
increased myeloid cells 
0/5   
E14 FL 1/14 345 95-100 slight splenomegaly 
reduced B cells 
increased myeloid cells 
increased T cells 
increased ckit+ cells 
1/10 6 expansion of 
recipient 
myeloid cells 
2/14 150-186 0-10 slight hepatomegaly 
expansion of recipient T 
cells  
Secondary 
E14 FL 1/10 280 95-100 splenomegaly 
increased myeloid cells 
increased T cells 
1/11 0 splenomegaly 
slight 
hepatomegaly 
reduced 
recipient 
leukocytes 
 
